[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605305":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":31,"collaborators":11,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":11,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":11,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":11},{"fullName":5,"class":6},"Onconic Therapeutics Inc.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: JP-1366 A mg + Placebo","EXPERIMENTAL",null,[13],"Drug: JP-1366 + placebo",{"label":15,"type":10,"description":11,"interventionNames":16},"Group 2: JP-1366 B mg + Placebo",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"Placebo + Placebo","PLACEBO_COMPARATOR",[21],"Drug: Placebo + Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","JP-1366 + placebo","taking JP-1366 + placebo",[9,15],{"type":24,"name":18,"description":29,"armGroupLabels":30,"otherNames":11},"taking placebo + placebo",[18],{"type":32,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605305","phase-3-phase-3-study-of-jp-1366-efficacy-and-safety-of-jp-1366-in-patients-with-non-erosive-gastroesophageal-reflux-disease-100605305",false,"NCT07160790","Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease","Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux(NERD) Disease: Double-blind, Randomized","Inclusion Criteria:\n\n* Subjects who have experienced both heartburn and acid regurgitation\n* Subjects in whom no mucosal breaks were observed on upper GI endoscopy at Visit 1 by LA Classification\n* Subjects who fully understand this clinical trial and voluntarily signed the informed consent form\n\nExclusion Criteria:\n\n* Subjects who have significant gastrointestinal diseases or procedures affecting the esophagus, stomach, or duodenum\n* Subjects who have a history of recent substance abuse, malignancy, systemic autoimmune or immune deficiency diseases, refractory response to PPI\u002FP-CAB, hypersensitivity to study drugs, genetic metabolic disorders, or significant psychiatric conditions.\n* Subjects who showed clinically significant abnormalities in laboratory tests\n* Positive result in the H. pylori test\n* Pregnant or breast-feeding women\n* Subjects who require hospitalization are scheduled to undergo surgery during the study period, or have undergone major surgery requiring general anesthesia\n* Other people deemed unsuitable for participation in this study according to the medical opinion of the investigator","ALL","19 Years","75 Years",{"count":44,"type":45},321,"ESTIMATED","INTERVENTIONAL",[48],"PHASE3","This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD",[51],"Non-erosive Gastroesophageal Reflux Disease",[53,54],"Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease","NOT_YET_RECRUITING","2025-08-29",{"date":58,"type":59},"2025-09-08","ACTUAL",{"date":61,"type":45},"2025-09-02",{"date":63,"type":45},"2026-06-30",{"name":5,"class":6}]